AR067453A1 - CONJUGADOS PEPTIDO - POLIMERO - Google Patents

CONJUGADOS PEPTIDO - POLIMERO

Info

Publication number
AR067453A1
AR067453A1 ARP080102907A ARP080102907A AR067453A1 AR 067453 A1 AR067453 A1 AR 067453A1 AR P080102907 A ARP080102907 A AR P080102907A AR P080102907 A ARP080102907 A AR P080102907A AR 067453 A1 AR067453 A1 AR 067453A1
Authority
AR
Argentina
Prior art keywords
peptide
polimero
conjugados
peptido
polymer
Prior art date
Application number
ARP080102907A
Other languages
Spanish (es)
Original Assignee
Pharmassentia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmassentia Corp filed Critical Pharmassentia Corp
Publication of AR067453A1 publication Critical patent/AR067453A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un conjugado péptido-polímero de la siguiente formula: A-G1-L-G2-B, en el cual A es una porcion de polímero; Cada G1 y G2, en forma independiente, es un enlace o un grupo funcional conector; L es un alquenileno o porcion de alquinileno; y B es una porcion de péptido. También se divulga un método para preparar un conjugado péptido-polímero y su uso en el tratamiento de la infeccion por el virus de la hepatitis C y de la infeccion por virus de la hepatitis B Reivindicacion 4: El conjugado de acuerdo con la reivindicacion 3, en el cual B es una porcion de interferon.A peptide-polymer conjugate of the following formula: A-G1-L-G2-B, in which A is a polymer portion; Each G1 and G2, independently, is a link or a functional group connector; L is an alkenylene or alkynylene portion; and B is a portion of peptide. A method for preparing a peptide-polymer conjugate and its use in the treatment of hepatitis C virus infection and hepatitis B virus infection is also disclosed. Claim 4: The conjugate according to claim 3, in which B is a portion of interferon.

ARP080102907A 2007-07-05 2008-07-04 CONJUGADOS PEPTIDO - POLIMERO AR067453A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94809507P 2007-07-05 2007-07-05

Publications (1)

Publication Number Publication Date
AR067453A1 true AR067453A1 (en) 2009-10-14

Family

ID=40226541

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102907A AR067453A1 (en) 2007-07-05 2008-07-04 CONJUGADOS PEPTIDO - POLIMERO

Country Status (4)

Country Link
CN (1) CN101343318A (en)
AR (1) AR067453A1 (en)
TW (1) TW200911288A (en)
WO (1) WO2009006579A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408031A1 (en) * 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
EP1753779A2 (en) * 2004-05-19 2007-02-21 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Also Published As

Publication number Publication date
TW200911288A (en) 2009-03-16
CN101343318A (en) 2009-01-14
WO2009006579A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
BRPI0513370A (en) use of a combination of pegylated cyclosporine and interferon for treatment of hepatitis c (hcv)
WO2009044273A3 (en) Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2004080403A3 (en) Influenza virus vaccine
WO2007062107A3 (en) Immunostimulatory oligoribonucleotides
PE20090711A1 (en) CONSTANT REGION OF MUTANT ANTIBODY
UA94717C2 (en) Modified influenza virus for monitoring and improving vaccine efficiency
EA200901241A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
CY1115413T1 (en) FSH RECOVERED THAT INCLUDES ALPHA 2,3- AND ALPHA 2 ', 6-SIALYLATION
WO2002091989A3 (en) Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
MA32633B1 (en) Crystalline forms of a 2-thiazolyl-4-quinolinyloxy derivative, a potent inhibitor of vhc
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2006038908A3 (en) Ancestral and cot viral sequences, proteins and immunogenic compositions
PE20120425A1 (en) METHODS AND COMPOSITIONS BASED ON TYPE 2 PROTEIN OF SHIGA TOXIN
WO2009038026A1 (en) Ctl inducer composition
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2006085979A3 (en) Soluble forms of hendra and nipah virus g glycoprotein
WO2009066462A1 (en) Method for induction of cytotoxic t-cell, cytotoxic t-cell inducer, and pharmaceutical composition and vaccine each comprising the inducer
WO2008100547A3 (en) Compositions comprising lamiridosin, iridoids or derivatives thereof for treatment of hepatitis c or hepatitis b
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
NZ603854A (en) West nile virus vaccine
DK1778271T3 (en) Peptide for the treatment of herpes virus infections
EA201070282A1 (en) POLYMER PROTEIN CONJUGATES
AR067453A1 (en) CONJUGADOS PEPTIDO - POLIMERO

Legal Events

Date Code Title Description
FB Suspension of granting procedure